• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Indian Biotechnology Industry Report Product Image

Indian Biotechnology Industry Report

  • ID: 310356
  • February 2008
  • Region: India
  • 158 Pages
  • Cygnus Research

FEATURED COMPANIES

  • Aventis Pharma Limited
  • Biocon
  • Panacea Biotech
  • Rasi Seeds
  • Serum Institute of India
  • Shantha Biotechnics
  • MORE

The global biotechnology industry in 2006 stood at USD73.12 billion up by 15.49% compared to 2005, the industry fared well in terms of fund raising, increased number of alliances and IPOs raised in the same period. Research and development activity, which is the foundation of success for the industry, is receiving continuous support all across the world with total R&D spend contributing to almost 38% of industry revenues.

The revenue of the Indian biotechnology industry reached INR85.41billion in 2006-07, up 30.98% from INR 65.21 billion in 2005-06. In 2006-07, top Ten Indian Companies reported revenue of INR 37.74 billion. The biotechnology industry is highly research and development (R&D) intensive. Globally, about 37.9% of revenue is spent on finding and developing new products. Although data relating to biotech R&D in India is not available, anecdotal evidence suggests that major companies are spending considerable amounts on biotech R&D, following their newfound focus on biotechnology.

The Report on Indian biotechnology gives information on the core technologies in biotechnology with reference to bio processing, monoclonal antibody, bio-nanotechnology etc. Indian biotechnology report describes major clusters region wise. It provides information on the regulatory bodies and the regulations in biotech industry along with the regulatory structure. It helps in knowing the critical success factors in biotechnology industry with reference to mergers & Acquisitions, product portfolio etc. At the end the report gives a future outlook for biotechnology industry.

FEATURED COMPANIES

  • Aventis Pharma Limited
  • Biocon
  • Panacea Biotech
  • Rasi Seeds
  • Serum Institute of India
  • Shantha Biotechnics
  • MORE

1.EXECUTIVE SUMMARY

3. BIOTECH INDUSTRY – GLOBAL OVERVIEW
3.1 Introduction
3.2 Industry growth
3.2.1 Concentric industry
3.2.2 Industry analysis
3.2.3 Research and development expenditure
3.2.5 Financial flow
3.3 Top ten biotech companies
4.1 Introduction
4.2 Milestones
4.3 The Indian Biotechnology Industry
4.3.1 Size
4.3.2 Industry segments
4.3.3 Exports
4.4 IPOs – Start of a new era
4.4.1 The price of success
4.5 Government Support
4.6 Funding
4.6.1 Government Funding
4.6.2 Private Funding

5. GROWTH DRIVERS
5.1 Introduction
5.2 Positive Regulatory Support
5.3 Availability of finance
5.4 Changing demographics & improved living standards
5.5 Growing Business Community
5.6 Growth of Related Industries
5.7 Knowledge Environment
5.8 Outsourcing

6. MAJOR PLAYERS
6.1 Serum Institute of India
6.2 Biocon
6.3 Panacea Biotech
6.4 Rasi Seeds
6.5 Venkateshwara Hatcheries
6.6 Aventis Pharma Limited
6.7 Glaxo Smithkline Pharmaceuticals
6.8 Shantha Biotechnics
6.9 Bharat Serums and Vaccines
6.10 Wockhardt

7. TECHNOLOGY
7.1 Core technologies
7.1.1 Bioprocessing
7.1.2 Monoclonal antibody
7.1.3 Cell/ tissue culture
7.1.4 Cloning
7.1.5 Recombinant DNA technology
7.1.6 Protein engineering
7.1.7 Biosensors
7.1.8 Bio–Nanotechnology
7.1.9 Microarrays
7.2 Other uses of biotechnology
7.3 Outlook
7.3.1 Pharmacogenomics
7.3.2 Metabolomics
7.3.4 Gene therapy
7.3.5 Immuno (Hybridoma) Technology
7.3.6 Stem cell techniques
7.3.7 Nutraceuticals
7.3.8 Bioremediation
7.3.9 Bioinformatics

8. MAJOR CLUSTERS
8.1 Southern Region
8.1.1 Andhra Pradesh-Hyderabad
8.1.2 Karnataka-Bangalore
8.1.3 Tamil Nadu-Chennai
8.2 Northern region
8.2.1 National Capital Region- Delhi
8.2.2 Uttar Pradesh (Lucknow) & Punjab (Chandigarh)
8.3 Western Region
8.3.1 Maharashtra–Mumbai & Pune
8.3.2 Gujarat
8.4 North Eastern Region
8.4.1 West Bengal–Kolkata
8.4.2 Assam– Gauhati

9. ISSUES AND CHALLENGES
9.1 Funding
9.2 Indian biotech start-ups & Foreign VCs
9.3 Biotech Manpower
9.4 Big pharma & biotechnology
9.5 Scientific community & Business acumen
9.6 Multiple regulators
10. REGULATIONS
10.1 Regulatory bodies
10.1.1 Organizational Structure of Relevant Institution
10.2 Regulatory Structure
10.3 Highlights of State Government Biotech Policies
10.3.1 Andhra Pradesh Biotech Policy
10.3.2 Maharashtra Biotech Policy
10.3.3 Gujarat Biotech Policy
10.3.4 Karnataka Biotech Policy
10.3.5 Tamil Nadu Biotech Policy
10.3.6 Himachal Pradesh Biotech Policy
10.3.7 Orissa Biotech Policy

11. CRITICAL SUCCESS FACTORS
11.1 Research & Development
11.2 Infrastructure
11.2.1 Premises and infrastructure
11.2.2 Biotech clusters
11.2.3 Effective networks
11.4 Mergers and Acquisitions
11.5 Product Portfolio

12. FUTURE OUTLOOK ANNEXURE 1 ANNEXURE 2

FEATURED COMPANIES

  • Aventis Pharma Limited
  • Biocon
  • Panacea Biotech
  • Rasi Seeds
  • Serum Institute of India
  • Shantha Biotechnics
  • MORE

The 21st century is witnessing the dawn of biotechnology, which is expected to surpass Information Technology as the new engine of the global economy. Biotechnology is expected to alter healthcare, agriculture, commercial and industrial products. The global biotechnology industry in 2006 stood at USD73.12 billion up by 15.49% compared to 2005, the industry fared well in terms of fund raising, increased number of alliances and IPOs raised in the same period. Research and development activity, which is the foundation of success for the industry, is receiving continuous support all across the world with total R&D spend contributing to almost 38% of industry revenues.

The Indian biotechnology industry, owing to its small size, was insulated from the boom-bust cycle. It has been growing at a strong pace in recent years, adding value to pharmaceuticals, agriculture and industry. The revenue of the Indian biotechnology industry reached INR85.41 billion in 2006-07, up 30.98% from INR 65.21 billion in 2005-06. In 2006-07, top Ten Indian Companies reported revenue of INR 37.74 billion. In 2006-07, Biopharmaceuticals accounted for 69.93% of industry revenue, followed by bioservices (12.90%), bio agriculture sector (10.84%), bioindustry (4.62%) and bioinformatics (1.70%).

The Biotechnology industry in India is using latest technology tools to speed the processes, by using the core technologies like BioProcessing, monoclonal anti body and cell tissue culture. After the invention of genetics and discovery of DNA structure and functioning, biotechnology evolved into a separate science. Recombinant DNA technology (rDNA) assists in every field-related to biotechnology. In the last decade, biotechnology has focused on chronic diseases. With the help of biotechnology tools and the application of computers, many problems in health and agricultural sector have been solved.

Biotechnology is also likely to have a significant impact on industrial and energy sectors. Many industries are already using enzymes in manufacturing processes because of their superiority over chemical catalysts and reagents. Biotechnology is also helping address growing energy needs through biofuels such as biodiesel and bioethanol.

The critical success factors for biotech industry in India are infrastructure in terms of premises effective channels of distributions trained manpower, drug imports, mergers and acquisitions with global companies and increasing the range of the product portfolio. The bio clusters in different regions in India also play an important role in developing the infrastructure for the industry.

The Biotech Policy, formulated by the Department of Biotechnology, at the union government level and biotech policies at the state level are encouraging entrepreneurs within and outside the country to promote biotech ventures in India. Now states in India are competing with each other to attract biotech investments. The government is also promoting biotechnology parks, valleys and clusters to provide world-class infrastructure to biotech ventures. The units located in such facilities are also eligible for tax incentives.

The biotech industry is growing due to factors such as the availability of emerging therapy areas, which facilitate all possible discoveries in industry, positive regulatory support from the government, improving demographics and various funding opportunities. The growth of related industries like pharma, bioservices, biopharma and other segments also help in stable growth to the Indian biotech industry. The educational institutions like the universities, science and biotechnology colleges which impart specialised courses in the biotechnology help in providing with the trained and skilled personnel to biotechnology companies

The Indian biotechnology industry, worth INR 85.41 billion (USD2.18 billion), has 340 biotech companies and 180 biotechnology suppliers. Some analysts believe that the Indian biotechnology industry could be worth USD25 billion by 2015. Serum Institute of India, a home-grown vaccines manufacturer with international reputation tops the list in terms of turnover with INR 9.5 billion. Biocon is relegated to the second position this year also with a biotech turnover of INR 8.2 billion. The next to Biocon is Panacea biotech which has INR 6 billion turnover in 2006-07.The highest percentage change was shown by Nuziveedu Seeds with a growth of 262.17%. Its revenue rose from INR 0.63 billion in 2005-06 to 2.26 billion in 2006-07.

By all accounts, the Indian biotechnology industry is set to transform pharmaceuticals, agriculture and industry. The Indian biotechnology sector in India, in view of its potential growth factor, is expected to reach INR 430 billion mark by FY2012 with a consecutive CAGR rate of 38.15%. Applications of biotechnology to diagnostic testing are speeding up and simplifying the identification of diseases, while advances in pharmacogenics are allowing a better understanding of how the human body responds to drugs, making it possible to develop more accurate and effective medications. Gene therapy brings the possibility of directly correcting genetic disorders and could lead to cures for these disorders instead of treatments.

Serum Institute of India
Biocon
Panacea Biotech
Rasi Seeds
Venkateshwara Hatcheries
Aventis Pharma Limited
Glaxo Smithkline Pharmaceuticals
Shantha Biotechnics
Bharat Serums and Vaccines
Wockhardt

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos